Local biopharmaceutical firm Adimmune Corp (國光生技) made public on Friday its intention to become the only supplier in Taiwan of a human vaccine against A(H1N1), a new influenza strain that broke out in Mexico in April.
Adimmune spokesman Kao Sheng-kai (高勝凱) made the declaration after a tender held by the Department of Health (DOH) earlier in the day for 5 million doses of the vaccine failed because only Adimmune submitted a bid.
The law governing governmental tenders requires that at least three companies submit bids for a tender to be valid.
SECOND ROUND
The DOH, however, will open a second tender next week that according to the Government Procurement Act (政府採購法) will not require a minimum number of bidders or a preset price range, Centers for Disease Control Deputy Director-General Lin Ding (林頂) said.
Kao said that his company, also known as Kuo Kwang Biotechnology Co, intends to vie for the business and become the government’s main supplier of the vaccine.
Foreign suppliers, already unable to meet demand in international markets and unlikely to be able to comply with the government’s targeted October delivery date, have not shown any desire to participate in tenders for the (A)H1N1 vaccine.
PRICE
Kao said the price of the vaccine for swine flu, which in recent months has spread around the world, has been on the rise because of increasing demand, including the US requirement of some 600 million doses.
Using the case of Novartis AG as an example, Kao said that the Switzerland-based drug company sold the vaccine at between US$8 and US$10 per dose to early buyers, but that this has recently increased to more than US$10 per dose.
Adimmune general manager Ignatius Wei (魏逸之) said the company’s price for the vaccine would be below US$10 per dose, but Kao said on Friday that the final price would be decided by the company’s board of directors.
CONDITIONS
The DOH said the government had planned to purchase the vaccine at a price of NT$200 per dose, but it would be allowed to raise its purchase price in the second tender.
The only private human vaccine manufacturing company in Taiwan said that it has purchased 8 million chicken eggs to produce the human vaccine against (A)H1N1 using chicken embryos.
Kao indicated that the company has begun the process of producing more than 1.5 doses from one egg, and he estimated Adimmune could produce between 7.5 million and 10 million doses of the vaccine with its available egg stocks.
DOSES
The DOH would purchase 10 million doses of the (A)H1N1 virus vaccine, 5 million doses of seasonal flu vaccine, and 900,000 doses of the antiviral drug Relenza this year to strengthen its anti-pandemic arsenal, Lin said.
So far, the DOH has secured 2.28 million doses of vaccine against seasonal flu, including 400,000 doses for children, Lin said.
TECH PARTNERSHIP: The deal with Arizona-based Amkor would provide TSMC with advanced packing and test capacities, a requirement to serve US customers Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is collaborating with Amkor Technology Inc to provide local advanced packaging and test capacities in Arizona to address customer requirements for geographical flexibility in chip manufacturing. As part of the agreement, TSMC, the world’s biggest contract chipmaker, would contract turnkey advanced packaging and test services from Amkor at their planned facility in Peoria, Arizona, a joint statement released yesterday said. TSMC would leverage these services to support its customers, particularly those using TSMC’s advanced wafer fabrication facilities in Phoenix, Arizona, it said. The companies would jointly define the specific packaging technologies, such as TSMC’s Integrated
China’s economic planning agency yesterday outlined details of measures aimed at boosting the economy, but refrained from major spending initiatives. The piecemeal nature of the plans announced yesterday appeared to disappoint investors who were hoping for bolder moves, and the Shanghai Composite Index gave up a 10 percent initial gain as markets reopened after a weeklong holiday to end 4.59 percent higher, while Hong Kong’s Hang Seng Index dived 9.41 percent. Chinese National Development and Reform Commission Chairman Zheng Shanjie (鄭珊潔) said the government would frontload 100 billion yuan (US$14.2 billion) in spending from the government’s budget for next year in addition
Sales RecORD: Hon Hai’s consolidated sales rose by about 20 percent last quarter, while Largan, another Apple supplier, saw quarterly sales increase by 17 percent IPhone assembler Hon Hai Precision Industry Co (鴻海精密) on Saturday reported its highest-ever quarterly sales for the third quarter on the back of solid global demand for artificial intelligence (AI) servers. Hon Hai, also known as Foxconn Technology Group (富士康科技集團) globally, said it posted NT$1.85 trillion (US$57.93 billion) in consolidated sales in the July-to-September quarter, up 19.46 percent from the previous quarter and up 20.15 percent from a year earlier. The figure beat the previous third-quarter high of NT$1.74 trillion recorded in 2022, company data showed. Due to rising demand for AI, Hon Hai said its cloud and networking division enjoyed strong sales
Protectionism: US trade chief Katherine Tai said the hikes would help to counter unfair trade practices from China, while boosting domestic clean energy investments US Trade Representative Katherine Tai (戴琪) defended stiff tariff hikes against countries such as China, saying that paired with investment, they were a “legitimate and constructive” tool for reinvigorating domestic industries. Tai’s comments come a week after sharp tariff increases on Chinese electric vehicles (EVs), EV batteries and solar cells took effect — with levies down the line on other products also recently finalized. The latest moves targeting US$18 billion in Chinese goods come weeks before next month’s US presidential election, with Democrats and Republicans pushing a hard line on China as competition between Washington and Beijing intensifies. In an interview on Thursday
RSS